Madrigal Pharmaceuticals, Inc. Annual Reports (10-K)
Every annual report 10-K going back 11 years. Put here in one place for you.
Page 1 of 11
2025-2012
| Currency in USD | 2025 |
|---|---|
| Operating Income | -300.1 Million |
| Income Before Tax | -288.28 Million |
| Income Tax Expense | 0.00 |
| Net Income | -288.28 Million |
| Eps | -12.85 |
| Epsdiluted | -12.85 |
| Weighted Average Shs Out | 22.43 Million |
| Weighted Average Shs Out Dil | 22.43 Million |
| Research And Development Expenses | N/A |
| Selling General And Administrative Expenses | 813.83 Million |
| Depreciation And Amortization | 1.51 Million |
| Interest Expense | 22.31 Million |
| Interest Income | 37.36 Million |
| Net Interest Income | 15.05 Million |
| Premiums Earned | N/A |
| Policyholder Benefits | N/A |
| Gross Profit | 902.25 Million |
| Ebitda | -298.59 Million |
| Source | edgar |
| Ebit | -265.98 Million |